The Long Run with Luke Timmerman

Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience

Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders

Spyre Therapeutics is redefining the treatment landscape for inflammatory bowel disease (IBD) by developing long-acting, co-formulated antibody therapies. CEO Cameron Turtle explains that by utilizing YTE modifications to extend drug half-life, the company enables infrequent dosing—potentially quarterly or twice-yearly...

Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets

Parabilis Medicines CEO Mathai Mammen details his transition from academic research and large-pharma leadership to pioneering alpha helical peptide technology. The company’s platform utilizes stabilized peptides to target "undruggable" proteins lacking traditional binding pockets, such as the beta-catenin/TCF complex. ...

Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus

Gary Nabel, CEO of ModeX Therapeutics, details the evolution of vaccine development and the transition toward multi-specific biologics. Moving beyond traditional single-target approaches, modern antibody engineering enables the creation of therapies that hit multiple viral or tumor targets simultaneously, effectively p...

Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases

Maze Therapeutics CEO Jason Coloma details his transition from academic research to biotech leadership, emphasizing the power of human genetics in drug discovery. The company leverages large-scale datasets, such as the UK Biobank, to identify genetic variants that protect against or cause complex conditions like chroni...

Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases

Developing inhalable treatments for rare, severe lung diseases like idiopathic pulmonary fibrosis (IPF) offers a path to improve patient outcomes where oral therapies fail. Avalyn Pharma reformulates existing oral drugs into inhalable versions, delivering medication directly to the lungs to minimize systemic side effec...

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

Ep204: Troy Wilson on Precision Cancer Drugs and Combos

The development of novel cancer therapies requires a long-term commitment to scientific innovation and strategic business execution. Troy Wilson, co-founder and CEO of Kura Oncology, details the company's path from early-stage R&D to the FDA approval of Ziftomenib, a first-in-class menin inhibitor for acute myeloid leu...

Ep203: Sri Kosuri on Small Molecule Correctors of Disease

Ep202: Becky Pferdehirt on Reimagining Science for the AI Era

Ep201: Jeremy Levin on Biotech in the Balance

The biotechnology industry faces an existential crisis of public trust, largely stemming from its perceived alignment with the pharmaceutical sector and a failure to articulate its unique value as a driver of innovation. To regain public support and ensure long-term stability, the industry must adopt a new social contr...

Ep200: Richard Pops on Orexin Drugs For Sleep Disorders & More

Richard Pops, long-time CEO of Alkermes, reflects on his 35-year tenure and the company's evolution from a small CNS-focused lab into a profitable developer of proprietary medicines. Orexin receptor agonists represent a breakthrough in treating narcolepsy, with potential applications for fatigue in neurological conditi...

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

Ep196: Otello Stampacchia on Europe's Biotech Crisis

European biotech's competitive position in the global landscape is at risk due to geopolitical pressures and financial constraints. Otello Stampacchia of Omega Funds discusses Europe's need to mobilize public and private capital to support its biotech industry, which currently receives only 7% of global venture capital...

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery

Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines

Ep192: Kate Haviland on Following the Science to Precision Immunology